Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

498 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score.
Carbone M, Nardi A, Flack S, Carpino G, Varvaropoulou N, Gavrila C, Spicer A, Badrock J, Bernuzzi F, Cardinale V, Ainsworth HF, Heneghan MA, Thorburn D, Bathgate A, Jones R, Neuberger JM, Battezzati PM, Zuin M, Taylor-Robinson S, Donato MF, Kirby J, Mitchell-Thain R, Floreani A, Sampaziotis F, Muratori L, Alvaro D, Marzioni M, Miele L, Marra F, Giannini E, Gaudio E, Ronca V, Bonato G, Cristoferi L, Malinverno F, Gerussi A, Stocken DD, Cordell HJ, Hirschfield GM, Alexander GJ, Sandford RN, Jones DE, Invernizzi P, Mells GF; Italian PBC Study Group and the UK–PBC Consortium. Carbone M, et al. Among authors: invernizzi p. Lancet Gastroenterol Hepatol. 2018 Sep;3(9):626-634. doi: 10.1016/S2468-1253(18)30163-8. Epub 2018 Jul 13. Lancet Gastroenterol Hepatol. 2018. PMID: 30017646 Free PMC article.
Better end points needed in primary sclerosing cholangitis trials.
Gerussi A, Invernizzi P. Gerussi A, et al. Among authors: invernizzi p. Nat Rev Gastroenterol Hepatol. 2019 Mar;16(3):143-144. doi: 10.1038/s41575-019-0110-5. Nat Rev Gastroenterol Hepatol. 2019. PMID: 30655632 No abstract available.
Dexamethasone Conjugation to Biodegradable Avidin-Nucleic-Acid-Nano-Assemblies Promotes Selective Liver Targeting and Improves Therapeutic Efficacy in an Autoimmune Hepatitis Murine Model.
Violatto MB, Casarin E, Talamini L, Russo L, Baldan S, Tondello C, Messmer M, Hintermann E, Rossi A, Passoni A, Bagnati R, Biffi S, Toffanin C, Gimondi S, Fumagalli S, De Simoni MG, Barisani D, Salmona M, Christen U, Invernizzi P, Bigini P, Morpurgo M. Violatto MB, et al. Among authors: invernizzi p. ACS Nano. 2019 Apr 23;13(4):4410-4423. doi: 10.1021/acsnano.8b09655. Epub 2019 Mar 18. ACS Nano. 2019. PMID: 30883091
Novel biomarkers for primary biliary cholangitis to improve diagnosis and understand underlying regulatory mechanisms.
Bombaci M, Pesce E, Torri A, Carpi D, Crosti M, Lanzafame M, Cordiglieri C, Sinisi A, Moro M, Bernuzzi F, Gerussi A, Geginat J, Muratori L, Terracciano LM, Invernizzi P, Abrignani S, Grifantini R. Bombaci M, et al. Among authors: invernizzi p. Liver Int. 2019 Nov;39(11):2124-2135. doi: 10.1111/liv.14128. Epub 2019 May 15. Liver Int. 2019. PMID: 31033124
Precision medicine in primary biliary cholangitis.
Ronca V, Gerussi A, Cristoferi L, Carbone M, Invernizzi P. Ronca V, et al. Among authors: invernizzi p. J Dig Dis. 2019 Jul;20(7):338-345. doi: 10.1111/1751-2980.12787. Epub 2019 Jul 10. J Dig Dis. 2019. PMID: 31099953 Review.
Antitumor Activity of a Novel Fibroblast Growth Factor Receptor Inhibitor for Intrahepatic Cholangiocarcinoma.
Raggi C, Fiaccadori K, Pastore M, Correnti M, Piombanti B, Forti E, Navari N, Abbadessa G, Hall T, Destro A, Di Tommaso L, Roncalli M, Meng F, Glaser S, Rovida E, Peraldo-Neia C, Olaizola P, Banales JM, Gerussi A, Elvevi A, Droz Dit Busset M, Bhoori S, Mazzaferro V, Alpini G, Marra F, Invernizzi P. Raggi C, et al. Among authors: invernizzi p. Am J Pathol. 2019 Oct;189(10):2090-2101. doi: 10.1016/j.ajpath.2019.06.007. Epub 2019 Jul 24. Am J Pathol. 2019. PMID: 31351075 Free article.
498 results